Skip to main content

AIM ImmunoTech Inc.

AIM
Exchange
NYSE
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0000946644

In the last 90 days, AIM ImmunoTech Inc. insiders filed 4 open-market purchases and 0 sales; 18 institutions reported holding it in 13F filings for Q2 2026, worth $325.6K in total; no superinvestor holds it.

Key figures

Insider buysLast 90 days, $13.5K in total
4
Insider sellsOpen market, last 90 days
0
13F holdersQ2 2026, 0 vs. previous quarter
18
13F valueReported value at the end of Q2 2026
$325.6K
Superinvestors holdingAt the end of Q2 2026
0

Price chart

Superinvestors holding AIM, Q2 2026

Go to the superinvestors tab

No superinvestor reported holding AIM at the end of Q2 2026.

Latest insider trades

Open-market purchases and sales by AIM ImmunoTech Inc. insiders from Form 4, newest first.

See all insider trades
Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Sep 18, 2026 (view filing)8:30 AM ETSep 171 dayEquels Thomas KCEO & PresidentPPurchase+24.0K$0.208+$4.99K+23.3%126.8K after
Sep 17, 2026 (view filing)12:01 PM ETSep 161 dayEquels Thomas KCEO & PresidentPPurchase+11.0K$0.21+$2.31K+12.0%102.8K after
Sep 16, 2026 (view filing)9:15 AM ETSep 151 dayEquels Thomas KCEO & PresidentPPurchase+22.0K$0.221+$4.86K+31.5%91.8K after
Sep 15, 2026 (view filing)4:30 PM ETSep 141 dayEquels Thomas KCEO & PresidentPPurchase+5.90K$0.219+$1.29K+9.2%69.8K after
Jun 16, 2025 (view filing)Jun 133 daysEquels Thomas KCEO & PresidentPPurchase+107$7.70+$823.9+0.3%38.9K after
Jun 13, 2025 (view filing)Jun 121 dayEquels Thomas KCEO & PresidentPPurchase+103$8.70+$896.1+0.3%38.7K after
Apr 23, 2025 (view filing)4:35 PM ETApr 1112 daysLateMitchell William MDirectorPPurchase+196.9K$0.0254+$5.00K+60.6%521.7K after
Apr 23, 2025 (view filing)4:35 PM ETApr 1112 daysLateEquels Thomas KCEO & PresidentPPurchase+1.97M$0.0254+$50.0K+103.7%3.87M after
Apr 23, 2025 (view filing)4:35 PM ETApr 1112 daysLateKellner Ted DDirectorPPurchase+1.97M$0.0254+$50.0K+196,850.4%1.97M after
Apr 7, 2025 (view filing)3:42 PM ETApr 43 daysEquels Thomas KCEO & PresidentPPurchase+41.0K$0.063+$2.58K+2.2%1.90M after

Top 10 13F holders, Q2 2026

The largest institutional positions in AIM ImmunoTech Inc. at the end of Q2 2026; share changes are against Q1 2026.

See all 18 holders
Institutions holding AIM in Q2 2026
InstitutionSharesValue% of portfolioChange in sharesAction
Jane Street Group, LLC807,885$229.4K0.00%+787,838+3,930.0%Added
Virtu Financial LLC124,269$35.0K0.00%+73,374+144.2%Added
Morgan Stanley50,864$14.4K0.00%+50,000+5,787.0%Added
Geode Capital Management, LLC46,003$13.1K0.00%+16,085+53.8%Added
Goldman Sachs Group Inc32,444$9.21K0.00%+32,444New
UBS Group AG28,931$8.22K0.00%+28,930+2,893,000.0%Added
Susquehanna International Group, LLP21,859$6.21K0.00%+21,859New
Vanguard Fiduciary Trust Co17,519$4.97K0.00%00.0%Unchanged
Ground Swell Capital, LLC12,222$3.47K0.00%+12,222New
Tower Research Capital LLC (TRC)4,668$1.33K0.00%00.0%Unchanged